March 2011. Volume 7. Number 1

Would it make sense extend to men vaccination against human papillomavirus?

 
 
 
 
 
 
 
 
 
 
Rating: 4 (1 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Elbasha EH, Dasbach E. Impact of vaccinating boys and men against HPV in the United States. Vaccine. 2010;28:6858-67.
Reviewers: Molina Arias M1, González de Dios J2.
1Servicio de Gastroenterología. Hospital Infantil Universitario La Paz. Madrid. Madrid. España.
2Departamento de Pediatría. Hospital General Universitario de Alicante. España.
Correspondence: Manuel Molina Arias. Email: mmolina.hulp@salud.madrid.org
Reception date: 17/01/2011
Acceptance date: 09/02/2011
Publication date: 16/02/2011

Abstract

Authors' conclusions: HPV vaccination programs provide substantial potential public health and economic benefits. Including boys and men 9-26 years of age would further reduce HPV-related morbidity and mortality and improve population's quality of life.

Reviewers' conclusions: these results do not appear to be consistent enough to broad the current HPV-vaccination recommendations to include men and boys. Although the inclusion of males would provide some benefits, these benefits could be obtained in greater amount and at lower economic cost by improving health care education and broadening the current vaccination coverture among girls and women.

How to cite this article

Molina Arias M, González de Dios J. ¿Tendría sentido ampliar a varones la vacunación frente al virus del papiloma humano? Evid Pediatr. 2011;7:4.

AVC | Critically appraised articles

Elbasha EH, Dasbach E. Impact of vaccinating boys and men against HPV in the United States. Vaccine. 2010;28:6858-67.
Reviewers: Molina Arias M1, González de Dios J2.
1Servicio de Gastroenterología. Hospital Infantil Universitario La Paz. Madrid. Madrid. España.
2Departamento de Pediatría. Hospital General Universitario de Alicante. España.
Correspondence: Manuel Molina Arias. Email: mmolina.hulp@salud.madrid.org
Reception date: 17/01/2011
Acceptance date: 09/02/2011
Publication date: 16/02/2011

How to cite this article

Molina Arias M, González de Dios J. ¿Tendría sentido ampliar a varones la vacunación frente al virus del papiloma humano? Evid Pediatr. 2011;7:4.

References

  1. Valladares A, González de Dios J, Sacristán JA. Evaluación Económica en Medicina (II): métodos de evaluación económica y manejo de la incertidumbre asociada. Evid Pediatr. 2009;5:88.
  2. Fernández Oropesa C. Las múltiples caras del conflicto de intereses y sus implicaciones en la práctica clínica. Evid Pediatr. 2010;6:71.
  3. González de Dios J, Buñuel Álvarez JC. Las conclusiones de los metaanálisis financiados por la industria farmacéutica deben ser interpretadas con precaución. Evid Pediatr. 2007;3:6.
  4. Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ. 2009;339:b3384.
  5. Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis. 2004;10:1915-23.
  6. CDC´s Advisory Committee on Immunization Practices (ACIP). Summary report, Atlanta, Georgia [en línea][fecha de acceso: 15-I-2011]. Disponible en: http://www.cdc.gov/vaccines/recs/acip/downloads/min-jun09.pdf
  7. Martínez-González MA, Carlos S, De Irala J. Vacuna contra el virus del papiloma humano: razones para el optimismo y razones para la prudencia. Med Clin (Barc). 2008;131:256-63.
16/02/2011

Linked Comment